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Genome-wide association studies (GWAS) of psychiatric disorders have identified multiple 
genetic associations with such disorders, but better methods are needed to derive the underlying 
biological mechanisms that these signals indicate. We sought to identify biological pathways in 
GWAS data from over 60,000 participants from the Psychiatric Genomics Consortium. We 
developed an analysis framework to rank pathways that requires only summary statistics. We 
combined this score across disorders to find common pathways across three adult psychiatric 
disorders: schizophrenia, major depression and bipolar disorder. Histone methylation processes 
showed the strongest association, and we also found statistically significant evidence for 
associations with multiple immune and neuronal signaling pathways and with the postsynaptic 
density. Our study indicates that risk variants for psychiatric disorders aggregate in particular 
biological pathways and that these pathways are frequently shared between disorders. Our results 
confirm known mechanisms and suggest several novel insights into the etiology of psychiatric 
disorders.
Psychiatric disorders account for a large proportion of global disease burden1. They are 
clinical syndromes with largely unknown etiology whose classification has been developed 
on the basis of their observable symptomatology and course of illness. However, there is 
considerable evidence for strong heritability of these disorders, and recent work by the 
Psychiatric Genomics Consortium (PGC) using genome-wide association study (GWAS) 
data has demonstrated that a considerable proportion of this heritability is attributable to 
common genetic variants2 and has also shown clear evidence of shared genetic risk at 
individual loci3.
To make further progress in the treatment and prevention of these disorders, there is an 
urgent need to clearly identify the biological mechanisms and pathways underlying risk. 
However, the analyses available to date have focused primarily on single disorders and on 
gene-expression approaches (for example, in schizophrenia4) and, although interesting, such 
approaches are subject to potential confounding by the downstream effects of disorders and 
their treatment. Genetic pathway analysis methods for GWAS data have been developed5,6 
and aim to identify which biological pathways show an excess of etiological association. 
Though the power to detect pathway associations can be limited by lack of power in the 
original GWAS data, genome-wide ‘chip-heritability’ estimates3 demonstrate that the loci 
showing nominal significance, but with values below genome-wide significance cutoffs, 
contribute to a significant proportion of disease liability. Pathway analysis provides a way to 
separate the true signals among these loci from the noise. Furthermore, pathway analysis can 
translate GWAS signals into a level of understanding that is biochemical and/or system-
wide and can provide successful replication in the presence of allelic and locus 
heterogeneity7,8.
In psychiatric genetics, several reports have found significant association with biological 
processes using GWAS. Analyses of bipolar disorder provided evidence of association with 
hormone action and adherens junctions7,9,10. Activity of voltage-gated calcium ions was 
also implicated in a pathway analysis of a bipolar disorder GWAS data set11. We 
hypothesized that combining pathway-based GWAS signals across multiple related 
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disorders could be a powerful approach to identify pathways susceptible to genetic risk in 
neuropsychiatric disorders.
The PGC was established in 2007 (http://pgc.unc.edu)12 and has been conducting field-wide 
mega-analyses of genomic data for common and severe psychiatric disorders2,3,11,13–15. 
Summary data are now available for PGC phase 1 studies that comprise >60,000 study 
participants representing schizophrenia (SCZ), major depressive disorder (MDD), bipolar 
disorder (BIP), autism-spectrum disorder (ASD) and attention deficit–hyperactivity disorder 
(ADHD). We have previously reported cross-disorder analyses via a single-nucleotide 
polymorphism (SNP)/association-based approach3 and as estimated “chip-heritability” and 
genetic covariance via the genome-wide evidence2. We now extend this work, seeking to 
statistically identify the molecular pathways implicated by variants underlying genetic risk, 
the identification of which may have major impact on the understanding and future 
treatment of psychiatric disorders.
RESULTS
We summarize pathway data sets and provide gene membership in Supplementary Tables 1 
and 2, respectively. From an initial compiled set of 19,752 pathways across five gene set 
databases (GO, KEGG, Panther, Reactome, TargetScan), we restricted downstream analyses 
to the 4,949 pathways of size 10–200 genes.
Comparisons among methods
We first obtained pathway-level P values for each pathway for the five disorders (SCZ, 
MDD, BIP, ASD and ADHD) across the five methods (SETSCREEN, MAGENTA, 
INRICH, FORGE and ALIGATOR). Overall, methods were significantly correlated with 
each other (see Supplementary Fig. 1 and Supplementary Table 3). Using both disorder data 
(SCZ) and null data (permuted phenotypes), we noted a statistically significant degree of 
overlap among methods (Supplementary Fig. 1).
Deriving a method-wise and disorder-wise joint statistic
Pathways that achieve strong association using all five methodologies would be expected to 
be more robustly associated with disorder, owing to the differences between methods. We 
estimated a combined P value for each pathway (within each disorder) by calculating the 
average rank of each pathway within each method (ranks were used to ensure comparability 
between methods) and then comparing to a null distribution of expected ranks, built by 
drawing from the uniform distribution, accounting for intermethod correlation (Fig. 1; see 
Online Methods).
There was a significant degree of correlation of pathway-specific enrichment P values 
between disorders (Pearson correlation 0.2–0.3, Supplementary Table 4). Looking for 
pathways common to the adult disorders (SCZ, BIP, MDD), we then derived a combined 
statistic across disorders using Brown’s extension of Fisher’s combined P value16 (see 
Online Methods). Figure 2 shows quantile-quantile plots of P values from combining all 
methods across disorders. Supplementary Figure 2 shows quantile-quantile plots of 
combined P values for SCZ, BIP, MDD, ASD, ADHD and, for contrast, null and HIV 
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acquisition data. The former plots show a marked enrichment of significant P values, 
indicative of shared disease biology captured by the pathways tested. The null and HIV plots 
shows no enrichment of P values, indicating both that there is a lack of shared biology (as 
expected) and that our analysis does not cause a systematic inflation of significance. 
Similarly, the HIV data set showed no inflation.
Top pathways in individual adult-onset psychiatric disorders
We present the results for the different psychiatric disorder data sets in Supplementary Table 
5, obtained using our approach. We identified 10, 1 and 4 pathway(s) that are suggestively 
enriched (at an FDR q-value <0.1) with BIP, SCZ and MDD susceptibility alleles, 
respectively (Table 1). Note that the pathways showing enrichment may change as sample 
sizes increase.
Top pathways shared across adult psychiatric disorders
The degree of rank correlation between pathways across pairs of disorders was significant 
(Supplementary Tables 4 and 6), with 49 pathways with combined q-value <0.1 spanning 
the three adult disorders (Table 2, Supplementary Table 7). Of these, 16 are significant at q 
< 0.05, with the top pathway (GO:51568: histone H3-K4 methylation) having a q = 0.0003 
(Table 2). These results are more significant than those observed in any of the disorders 
analyzed alone. We then use multidimensional scaling (MDS) to cluster these sets in terms 
of shared genes. Figure 3 shows a plot of every pathway with suggestive q < 0.1 on the first 
two MDS axes derived from the shared genes between these gene sets. The pathways 
separate in multidimensional space and reveal two distinct branches for neuronal synapse– 
and histone methylation– related gene sets, with a third branch containing pathways with 
genes that share membership in pathways with immune or neurotrophic functional 
annotation (Fig. 3). Although not a main focus of our analysis, the most significant pathway 
(GO:0005262, calcium channel activity) from the previous PGC Cross Disorder group SNP-
based meta-analysis GWAS3 across the five disorders was found to show nominally 
significant association in our pathway level meta-analysis across all five disorders (P = 3.13 
× 10−3) and also in SCZ, MDD and BIP (P = 8.07 × 10−3).
Analysis of null and control disorder data
The enrichment P values of the pathways in Table 2 (and Supplementary Table 7), 
combined across SCZ, BIP and MDD, indicated that there are multiple significant pathways. 
To confirm that this was due to shared disorder biology, we repeated the rank-combining 
analysis on two further data sets as controls: a GWAS of HIV17, chosen because it is not 
thought to share significant disorder etiology with psychiatric disorders but might instead 
share real technical artifacts, and a null GWAS, simulated using the same SNPs as the 
psychiatric GWAS but with no significant loci. The most significant pathways for the HIV 
and null data sets analyzed separately are shown in Supplementary Table 4. As expected, no 
pathways showed significant enrichment in the null data set or HIV data set, and the SCZ, 
HIV and null data sets combined analysis (Supplementary Table 8) gave no significant 
pathways after multiple-testing correction (minimum q-value = 0.454), in contrast to the 
results for SCZ, MDD and BIP shown in Table 2. This gives further evidence that the 
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significant pathway enrichments in Table 2 are due to shared biology across all three 
disorders, rather than being driven by enrichments in any single disorder.
Follow-up of brain gene expression of significant pathways
To place these pathways in a more specific neurobiological context, we analyzed 
coexpression relationships between the genes in pathways identified here at q < 0.1 using 
gene-expression data spanning brain regions and developmental time points18. Out of 797 
genes assessed, 294 (32–37% of each branch from Fig. 3) were coexpressed in 7 modules. 
Figure 4a provides a network plot showing intramodular and intermodular connections 
between the top 10 hub genes in each module. Figure 4b summarizes the average expression 
level of genes in each module in different brain regions and temporal periods. These 
expression patterns are predominantly driven by temporal regulation (four modules have 
greater than twofold temporal change, while only one module, green, shows a twofold 
change between regions, Supplementary Table 9), suggesting that genetic risk across neuro-
psychiatric disorders affects neurodevelopmentally regulated pathways.
Of note, the yellow module is similarly expressed across regions and contains half (19/37) of 
the coexpressed histone methylation genes. Genes in this module exhibit over threefold 
higher average expression during early prenatal development (postconception week (PCW) 
13–24) than during postnatal development or later aging, consistent with histone genes 
primarily functioning during neuronal differentiation and cell-fate commitment. Complete 
module membership and network details are available in Supplementary Table 9, which 
contains complete information about module-region associations and module-stage 
associations. Three other modules predominantly contain immunological and neuronal 
signaling and synapse genes whose expression increases in childhood and plateaus around 
adolescence to late adulthood (blue, brown, turquoise); three other modules are relatively 
highly expressed throughout life with ~75% maximum difference in expression between 
regions (green, black and red modules).
We then asked whether these modules exhibited a cell type–specific pattern by using gene 
lists from 35 genetically tagged and translationally profiled cell types in mouse19–21. Two of 
the modules containing immune-neuronal signaling and synapse genes that plateau in 
expression in maturing brain also exhibited cell type enrichment, with the brown module 
enriched for striatal neurons, particularly Drd1+ medium spiny neurons, and the turquoise 
module enriched for Cnp+ myelinating oligodendrocytes, suggesting its involvement in 
white matter maturation. Other modules did not exhibit strong cell type specificity, 
suggesting that either they affect multiple cell lineages (for example, the yellow module) or 
the matching cell type profile has yet to be defined.
DISCUSSION
Major advances have occurred in psychiatric genetics over recent years, largely driven by an 
order-of-magnitude increase in sample sizes. While the identification of specific loci is 
critical to moving the field forward, so too is developing an understanding of the underlying 
biology. In this study we address the latter, integrating data from the largest reported 
psychiatric genetics data sets with well-established tools for interrogating such data sets. We 
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developed a novel rank-based method to combine pathway enrichment results across 
analysis methods and disorders in a manner that is not confounded by the biases or 
shortcomings of the methods, to maximize the informativeness of the results. This contrasts 
with the approach of the previous PGC Cross Disorder group GWAS4, which used a SNP-
based meta-analysis. Pathway analyses based on such results will be powerful if the same 
SNP is implicated across disorders. Importantly, the pathway analyses described here do not 
require the same SNP (or, indeed, gene) within a pathway to be implicated across disorders, 
so they will be more robust to allelic heterogeneity within genes and within pathways across 
disorders, thereby providing a conceptually more powerful framework for conducting 
analyses, while losing power compared to single-SNP-level analyses if the same SNPs are 
driving the association across related disorders. We note that the most significant pathway 
identified from the PGC cross-disorder analysis3 (GO:0005262, calcium channel activity) 
also showed nominally significant enrichment in our analysis, confirming a role for calcium 
channel activity in these disorders.
Our analysis method uses GWAS summary statistics rather than using phenotype 
permutations on individual genotype data for two reasons. First, the PGC data sets are large 
and highly complex (>50 separate data sets) with a mixture of study designs and covariates 
(for example, those modeling ethnic stratification). For example, the PGC autism and 
ADHD genotype data are mixtures between trio and case-control studies. All of these 
complexities greatly increase the computational time necessary, so we implemented a more 
efficient method. For example, using a permutation-based approach that performed 
sufficient permutations across all the different data sets to generate disorder-level P values 
would have been computationally prohibitive. In addition, it is not always possible to obtain 
individual genotype data, particularly for large meta-analyses. It is therefore important that a 
pathway analysis method is applicable in such situations.
The primary strength of our integrated GWAS pathway analysis approach is the use of 
multiple analysis methods that differ in their assumptions and individual strengths. Methods 
that combine individual SNP P values across genes and pathways (FORGE, SETSCREEN) 
will pick up pathways containing genes with multiple, perhaps weak, independent 
association signals. Conversely, methods such as ALIGATOR or INRICH assign 
significance to genes based on the single most significant SNP in that gene, and will thus 
detect enrichment to pathways containing genes with individually, stronger associations. 
Notably, despite these differences, all of these methods yielded pathway rankings that were 
correlated with each other (Supplementary Table 5). As expected, the strongest correlations 
were observed between the most similar methods: FORGE and SETSCREEN, and 
ALIGATOR and INRICH.
Biological themes within and across disorders
Our primary aim was to combine pathway associations across disorders, as we hypothesized 
that this would be a more powerful approach, and we show a large increase in the evidence 
arising after meta-analyzing across disorders. The correlation of pathway-specific 
enrichment P values between SCZ and BIP was the highest among all pairs of disorders 
(0.29, Supplementary Table 5), consistent with the reported genetic correlation using 
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common SNPs for these disorders4. Notably, combining the pathway-specific P values 
across the three ‘adult’ disorders in our primary meta-analysis (SCZ, BIP and MDD) 
resulted in greatly increased significance compared to the analyses of the separate disorders. 
This allowed us to identify biological themes spanning these disorders.
A secondary aim was to examine pathway themes within individual disorders, in order to 
show which disorders were contributing most to the cross-disorder findings. Among 
individual disorders, BIP, SCZ, MDD and ADHD gave significant results at FDR q < 10%, 
but ASD and HIV did not (Table 1 and Supplementary Table 4). Our results suggest that 
histone methylation appears to play a more prominent role in bipolar disorder and that 
synapse- and postsynapse-related processes are more strongly implicated in the etiology of 
schizophrenia (Table 1). We note that pathways involved in the methylation of other 
molecules, such as DNAs, were not highly enriched in this study, suggesting a degree of 
specificity in the nature of methylation gene sets implicated here. For schizophrenia, we note 
that “KEGG_DOPAMINERGIC_SYNAPSE” was reported as the third-highest-ranked 
pathway (of 9,016) in the latest GWAS data (analysis by ALIGATOR)22. Our top SCZ 
pathway—postsynaptic density—did not rank highly in either the ALIGATOR or INRICH 
analysis reported in that paper, but those pathway analyses were applied to a heavily 
restricted set of genes (those containing a SNP with P < 5 × 10−8) and used only two of our 
five analysis methods (ALIGATOR and INRICH), making that analysis not directly 
comparable with ours. We also include methods (FORGE, MAGENTA, SETSCREEN) that 
may favor more polygenic, complex patterns of association. Analyses presented here use a 
more relaxed significance criterion, thus picking up signals that do not reach genome-wide 
significance. We note that strong, independent support of our findings comes from the 
observation that analyses of rare variants have also implicated postsynaptic pathways in 
SCZ etiology23,24, suggesting that both rare and common variants are relevant.
Emerging landscape of psychiatric pathways
We show that synapse-related as well as newly implicated histone methylation and immune 
and neuronal signaling pathways are statistically significantly associated within and across 
SCZ, BIP and MDD. These pathways are core molecular processes, disruption of which may 
increase risk for multiple psychiatric disorders. Especially interesting in this regard is the 
identification of synaptic and immune dysfunction as the major pathways altered in 
postmortem brain in ASD25, as well as of emerging genetic overlap across many 
neurodevelopmental conditions. Our top results for schizophrenia, post-synaptic density, has 
been previously suggested by CNV findings and convergent lines of evidence23,26, as well 
as recent exome sequencing data27,28, suggesting a role for both rare and common variants 
in affecting SCZ-relevant changes in the postsynaptic membrane proteins. “Histone H3-K4 
methylation” featured among top bipolar hits, achieving study-wide significance (q = 0.005). 
Variable H3-K4 methylation of synapsin genes has been shown to give rise to altered 
expression patterns in bipolar disorder and major depression29, which may suggest a role for 
epigenetic regulatory mechanisms in the etiology of mood disorders. Histone methylation 
mechanisms have roles in the coordination of complex cognitive processes such as long-
term memory and roles in conditions from addiction to schizophrenia to 
neurodegeneration30.
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Recent studies of de novo mutations have also implicated this pathway (often referred to by 
a broader term, chromatin regulation/ modification or transcriptional regulation) in 
ASD31–33. However, our ASD data set, based on GWAS, did not have sufficient power 
(owing to both the smaller sample size available and the combination of case-control and 
trio data sets) and was excluded from the primary pathway analysis. For MDD alone the top 
pathway was “protein phosphatase type 2A regulator activity,” which achieved a q-value of 
0.012. Prior studies have implicated this pathway in serotonergic neurotransmission and in 
the mechanism of response to antidepressants34.
We excluded the schizophrenia-associated MHC region of 6p21–22 in our analysis to avoid 
confounding of methods by the very high levels of linkage disequilibrium at this locus. 
Despite this, key immune processes such as TGF-beta_signaling (P00052), 
B_cell_activation (P00010) and T_cell_activation (P00053) feature highly in our significant 
pathways. KEGG infectious disease pathways also featured at suggestive significance. 
Although these pathways contain immune processes, such as the Tuberculosis (hsa05152) 
and Hepatitis C (hsa05160) pathways, their role in the brain has been highlighted by, for 
example, studies finding that both hepatitis C infection and interferon alpha treatment for 
hepatitis C are associated with a range of additional neuropsychiatric symptoms35.
We also found pathway genome-wide association across SCZ, BIP and MDD with histone 
methylation (rather than DNA methylation) processes via Histone H3-K4 methylation (GO:
51568), Histone methylation (GO:16571), Histone lysine methylation (GO:34968) and 
Macromolecule methylation (GO:43414). Replicated environmental risks for schizophrenia 
occur at critical periods early in development, for example, in the Dutch Hunger Winter and 
Chinese famine studies36, when the epigenome is known to be particularly labile. At this 
time rapid cell replication is occurring and the standard epigenetic signals, including histone 
H3-K4 and lysine methylation and other related processes, are driving development and 
tissue differentiation37. Given the role of this process in establishing active promoters38, it 
appears likely that the dysregulation of histone methylation may have downstream effects 
with the potential to disrupt neurodevelopment and coordinated gene expression, as animal 
studies have demonstrated39. Our results suggest that dysregulation of the genes in histone 
methylation pathways is a common etiological mechanism for adult psychiatric disorders.
Our gene network analysis of how the identified pathways are expressed in brain revealed 
modules of coexpressed genes that identify developmental time points and brain regions that 
may inform future experiments aimed at manipulating the identified pathways (Fig. 4). 
Additionally, enrichment for cell type–specific transcriptomic signatures identifies which 
cellular subtypes may be affected upon manipulation of specific genes. For example, the 
temporal trajectory of modules suggests which pathways may not be amenable to 
pharmacologic manipulation as a result of their prominence in early development (for 
example, the yellow module which contains histone methylation genes), but also pathways 
whose activity is potentially modifiable in adults (for example, the brown and turquoise 
modules, which were enriched for genes specific to striatal neurons and white matter, 
respectively). Additionally, the blue module’s expression pattern is similar across regions, 
and the hub genes suggest both intracellular and intercellular signaling processes. It shows 
an increase during late prenatal and early postnatal development, peaking before age 6, 
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suggesting the genes in this module may be related to postnatal synaptic pruning, another 
potential target for developing interventions. We emphasize that these results should be 
considered preliminary, as they are a first-pass analysis using the results of a novel 
approach. Nevertheless, they do point a clear way forward for unbiased assessment of 
pathways affected by common genetic variation, which is expected to explain a majority of 
the genetic architecture of neuropsychiatric diseases. They suggest that the integration of 
gene expression with pathway-level analyses on larger GWAS can identify even greater 
specificity. Furthermore, future analyses can increase neurobiological specificity by 
searching across denser time point data or using cell type–specific transcriptomes acquired 
from single-cell sequencing in human brain, as they become available.
Our analyses have shown the general ability of pathway analyses to discover novel biology 
underlying complex human disorders. The immune-neuronal signaling and histone 
methylation findings illustrate how genetic risk aggregation in pathways may underlie 
vulnerability to environmental risk factors in the prenatal environmental, while 
strengthening the evidence for the role of synaptic pathways. Our results shed light on the 
biology underlying GWAS of psychiatric disorder and could suggest novel functional and 
drug discovery studies, as pathways make far larger and better drug targets than individual 
genes40. Our observation that the degree of correlation between pathways across disorders is 
higher than expected by chance builds on the observation of shared genetics between these 
disorders4 and, importantly, indicates that polygenic overlap is nonrandom at a molecular or 
pathway level.
ONLINE METHODS
Method rationale
The PGC (Psychiatric Genomics Consortium) has applied SNP association data3 and 
estimated “chip-heritability” estimate approaches2 to compare and contrast psychiatric 
disorders. Here we study the molecular pathways in which genetic risk for psychiatric 
disorders aggregate and examine whether or not these pathways are shared between related 
psychiatric disorders. The multiplicity of methods and parameters that can be used for such 
an undertaking led to the formation of a subgroup of the Psychiatric Genomics Consortium 
(http://pgc.unc.edu/) to develop a protocol and pipeline for five published methods of 
GWAS pathway analysis along with a methodology to combine results from different 
analytical methods to show the most robust pathway signals arising from GWAS data.
Samples and genotypes
The samples for these analyses (total N = 61,220) included cases, controls and family-based 
samples assembled for published genome-wide mega-analyses of individual-level data 
conducted by the PGC (see refs. 2,3,11,13–15 for details). To ensure comparability across 
samples, raw genotype and phenotype data for each study were uploaded to a central server 
and processed through the same quality control, imputation and analysis pipeline. This 
approach is detailed elsewhere11, but we describe it briefly here: to ensure independence of 
individual disorder analyses, only one of pair of related or duplicate individuals were 
retained, and in only one disorder case or control set, resulting in 61,220 cases and controls 
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in total. Stringent and standardized quality control procedures were applied as previously 
described3. For the family-based samples, alleles transmitted to affected offspring (“trio 
cases”) were matched with untransmitted alleles (“pseudo-controls”). The disorder samples 
comprised ASD (4,788 trio cases, 4,788 trio pseudo-controls, 161 cases, 526 controls), 
ADHD (1,947 trio cases, 1,947 trio pseudo-controls, 840 cases, 688 controls,), BPD (6,990 
cases, 4,820 controls), major depressive disorder (9,227 cases, 7,383 controls) and SCZ 
(9,379 cases, 7,736 controls). Identity-by-descent relationships were estimated for all pairs 
of individuals to identify any duplicate individuals across the component data sets. When 
duplicates were detected, one member of each set was retained. These individuals were then 
randomly apportioned to a single disorder case-control data set. All subjects were of 
European ancestry and met DSM-III-R or DSM-IV criteria for the primary disorder of 
interest.
Study sample numbers for individual disorders were: ASD (n = 4,949 affected/5,314 
unaffected), ADHD (n = 2,787/2,635), BIP (n = 6,990/4,820), MDD (n = 9,227/7,383) and 
SCZ (n = 9,379/7,736). Imputation was conducted using HapMap III data as references, 
resulting in over 1.2M SNPs. SNPs with imputation quality scores less than 0.8 were filtered 
out. Single SNP-based association analyses were conducted using logistic regression on 
individual disorders with ancestry covariates and GC-corrected. The MHC region on 
chromosome 6 (25–35 Mbp) was excluded from further analyses to prevent potential impact 
of extensive linkage disequilibrium (LD) in the region.
For all analyses, five P-value sets were used: schizophrenia (SCZ), 1,227,336 SNPs; bipolar 
disorder (BIP), 1,223,695 SNPs; major depressive disorder (MDD), 1,220,925 SNPs; 
ADHD, 1,219,982 SNPs; autism (ASD), 1,232,050 SNPs. Our primary analysis included 
SCZ, BIP and MDD.
We also analyzed a null GWAS sample, to assess the degree of dependence between 
methods, as well as to ensure that our analysis did not generate an excesive amount of false 
positives. This was generated from unrelated CEU+TSI Hapmap3 data sets via random 
assignment of case/control phenotypes (100 cases and 100 controls). PGC1 data involves 
only European subjects (imputed using Hapmap3 CEU+TSI panels) and thus the use of 
Hapmap3 European data most closely matches the LD structure of the PGC1 disease 
samples. Since the null sample by definition contains no true effects, power is not an issue. 
Therefore, the relatively small sample size is not important.
Gene and pathway data
We used Ensembl41 gene definitions as the reference gene annotation and map. We 
combined gene set data from six sources: KEGG, GO, PANTHER, TARGETSCAN, 
REACTOME and OMIM. An overview of our methodology is shown in Figure 1. All gene 
sets were downloaded from their respective sources (11 August 2011). The parsing of these 
sets is summarized in Supplementary Table 1 and summary statistics are given in 
Supplementary Table 2.
To ensure the specificity of gene set association findings, further analyses were restricted to 
4,949 gene sets of at most 200 genes and at least 10 genes (we limited our analysis to 
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pathways containing 10–200 genes because statistics for smaller gene sets were over-
dispersed and the few outlier sets with >200 genes were computationally inefficient to 
analyze and largely nonspecific due to the large number of genes (data not shown)). 
Identical pathways were removed. Overlap, measured by correlation between gene content 
across pathways, between the six gene set resources were minimal (R2 < 0.12). The different 
pathway sets were combined into one database and identical pathways merged.
Gene definitions
For all analyses, we used Ensembl identifiers as the master gene set, with −35 kb upstream 
and +10 kb downstream to define the gene boundaries, since transcriptional regulatory 
elements are likely to be contained within these intervals and that there is thus merit in 
capturing the variation within these regions42. Analysis was run both with and without the 
MHC region (chromosome 6, 25–35 Mb).
Standardization of pathway inputs
SNPs were assigned to genes based on human genome build 37 positions if they lay within 
35 kb upstream or 10 kb downstream of the gene. In total, 739,373 SNPs were assigned to 
18,689 genes. Note that if SNPs mapped within more than one gene, they were assigned to 
all such genes. SNPs were also filtered by imputation quality (INFO > 0.8), which resulted 
in 477,792–543,578 SNPs being assigned to 16,334–17,352 genes (these numbers vary 
slightly between disorders). We used a standardized framework of data input for our 
analyses. Empirical results (P values for individual SNPs) from PGC GWAS were gathered 
for each disorder, and all P values were GC-corrected. For all analyses, we used pathways 
with a minimum of 10 genes and a maximum of 200 genes.
Five published pathway analysis methods were used. These fell into two classes with 
differing approaches and assumptions regarding genomic architecture of risk variants in 
pathways as well as different methods for the correction of LD and gene size effects. 
FORGE43 and SET SCREEN TEST44 are meta-analysis methods that combine P values 
across all the SNPs in genes or pathways while adjusting for the confound of LD. 
INRICH45, ALIGATOR9 and MAGENTA46 are “best SNP per gene” methods that count 
the number of genes in a pathway where a number of independent SNPs exceed a predefined 
significance, and adjust for LD and genomic structure with corrected statistics derived by 
Monte-Carlo simulation. We describe these methods below.
FORGE method
FORGE is a software suite that implements a range of methods for the combination of P 
values for the individual genetic variants within a gene or genomic region while adjusting 
for linkage disequilibrium–induced correlations43. The software can be used with summary 
statistics (marker ids and P values) and accepts as input the result file formats of commonly 
used genetic association software. In addition, several utility programs are distributed with 
FORGE allowing users to (i) map SNP to genes using the Ensembl human genome 
annotation, (ii) parse different gene-set files, and (iii) calculate meta-analysis statistics for 
gene and gene-set analysis results when studies are carried out on multiple data sets. For 
each pathway, a nonparametric test yields a P value for enrichment of genes in a pathway 
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given the entire set of pathways analyzed. FORGE can be freely accessed at https://
github.com/inti/FORGE.
MAGENTA method
MAGENTA is an acronym for Meta-Analysis Gene-set Enrichment of variaNT Associations 
and is a program that takes as input summary P values from GWAS46. Testing for statistical 
significance of pathways using MAGENTA is a 3-step process. First, every gene is assigned 
the best GWAS P value that falls within that gene or the user-defined upstream and 
downstream regions of that gene. These P values are corrected, using multivariate linear 
regression, for known confounders of P values including gene size and linkage 
disequilibrium properties. Finally, for each pathway, the observed number of gene P values 
surpassing a certain user-specified threshold for P values (here 95%) is compared against 
expected number of gene P values surpassing that threshold for a given pathway size (i.e., 
number of genes). For each pathway, a nonparametric test yields a P value for enrichment of 
genes above the predetermined threshold.
Set screen test method
The set screen test is based on theoretical approximation of Fisher’s statistics such that the 
combination of P values at a gene or across a pathway is carried out in a manner that 
accounts for the correlation structure, or linkage disequilibrium, between single nucleotide 
polymorphisms. The approach is similar to that applied in FORGE (LD)43. The test is 
implemented in PLINK47. We applied this method to the PGC data, corrected for GC 
inflation, using CEU founders from HapMap to describe the LD structure. We used the same 
gene sets as described above which were filtered to contain no less than 2 and no more than 
200 genes. For a given pathway or set, we assigned a P value to the set when at least one 
SNP was present. Where more than one SNP was present, the combined P value (accounting 
for LD) was given.
ALIGATOR method
ALIGATOR converts a list of significant and nominally significant SNPs into a list of 
significant genes, and, for each predefined gene set, tests whether this gene list contains 
more genes from the gene set than would be expected by chance9. This is done by 
comparing the gene list to 100,000 random gene lists of the same length generated by 
sampling SNPs (not genes) at random, correcting for variable numbers of SNPs per gene and 
variable gene size. Correction for the multiple testing of non-independent gene sets is 
performed using a bootstrap method repeated 5,000 times. Gene sets require at least two 
signals to be counted as enriched to remove the possibility of a small gene set being deemed 
significantly enriched based on one signal. An important modification to the original 
ALIGATOR method is that significant genes in the same gene set that mapped less than 1 
Mb apart (and thus could be explained by the same association signal) are counted as a 
single signal. In this analysis, SNP-wise P value criteria for defining “significant” SNPs, and 
thus “significant” genes, were chosen so that the resulting list of significant genes contained 
the top 5% of all genes. When no filtering was performed, P value criteria varied from 8.4 × 
10−4 to 3.31 × 10−4 when the −35 kb/+10 kb gene window was used. When SNPs were 
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filtered by information score, the P values increased slightly, from 1.64 × 10−3 to 5.18 × 
10−3.
INRICH method
INRICH45 takes a set of independent, nominally associated genomic intervals and then tests 
for the enrichment of predefined gene sets. An interval will typically correspond to a 
genomic region of SNP association defined by LD from a genome-wide scan, although 
intervals could also represent regions identified as homozygous-by-descent, for example, 
deletion or duplication events observed in cases. The INRICH analysis procedure comprises 
three major steps: (i) linkage disequilibrium (LD)-based interval data generation to identify 
unique regions of association; (ii) empirical enrichment calculation using an interval-based 
permutation strategy; and (iii) second-step permutation for multiple testing correction at the 
gene set level. INRICH also presents global enrichment statistics Gp, and the empirical 
significance of Gp is evaluated within a permutation procedure.
Pathway analysis strategy
Given that the results of the five analysis methods are correlated but not identical, pathways 
genuinely involved in disease susceptibility would be expected to show consistent 
enrichment for association signal across several methods. Therefore, we ranked the 
pathways in ascending order of enrichment P value for each method and calculated the 
average rank of each pathway across all five methods. This analysis was carried out for each 
disease separately. The lower the average rank of a pathway, the more consistent its 
evidence for enrichment of association signal across the methods, and thus the greater the 
likelihood of involvement in disease susceptibility. Ranks were used to control for differing 
power of each method.
Our general approach is outlined in Figure 1. Our primary analysis sets consisted of the 
samples for the adult disorders of schizophrenia (SCZ), bipolar disorder (BIP) and major 
depressive disorder (MDD) as these three have the highest genetic relationship in the recent 
pair-wise analysis of the five psychiatric disorders using GWAS data2. Supplemental 
analyses were performed on attention deficit hyperactivity disorder (ADHD) and autism 
(ASD) data sets3,13. We used a Monte-Carlo simulation approach, modeling the dependence 
between methods in terms of the observed pairwise correlations of pathway enrichment P 
values to calculate the average rank and significance of a pathway in a disorder across all 
methods (Supplementary Analysis and Supplementary Tables 12–15). However, the analysis 
method and results are robust to variation in these correlations (Supplementary Tables 15 
and 16). The motivation for using ranks rather than P values was to ensure that all methods 
were treated equally. Specifically, FORGE and SET-SCREEN combine the P values of the 
SNPs, and it is therefore possible for them to achieve very small enrichment P values if the 
pathway contains strongly associated SNPs. This is not the case for ALIGATOR, INRICH 
and MAGENTA, which use simulation to give enrichment P values. Note also that INRICH 
and ALIGATOR require a pathway to contain two significant genes for an enrichment P 
value to be calculated. Thus, missing enrichment P values count as evidence against 
enrichment for these methods, and such pathways are assigned the joint bottom rank. It is 
possible that a pathway may rank relatively poorly on one method compared to the others, 
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thus reducing the power of the average rank to detect enrichment. We therefore performed a 
secondary analysis based on the average of the best four ranks. However, this had little 
effect on the results (see Supplementary Analysis and Supplementary Tables 12 and 13).
We calculated observed and expected overlaps between all combinations of methods to 
assess the extent of concordance between methods. For the top 10% ranked pathways in 
each disorder, we then compared observed and expected overlaps between all combinations 
of the three adult disorders.
Combination of pathway ranks across methods
Finally, we combined pathway P values across disorders using Brown’s method (an 
extension of Fisher’s method for correlated data). To ensure that the observed pathway 
enrichments across the disorders were a result of shared biology, rather than artifacts of the 
analysis method, we also applied our rank-based method to a null data set (simulated to have 
no phenotype effects) and a GWAS of HIV-1 acquisition17. HIV infection acquisition can be 
assumed to share little biology with the psychiatric disorders studied here because, although 
two MHC associations have been discovered, we excluded the entire extended MHC region 
from our analyses. The null and HIV data sets were tested individually, as well as in 
combination with the SCZ data set.
The following procedure yields a single combined P value for each pathway in a given 
disease data set by merging results across the 5 methods, accounting for correlation. For 
each disease, do the following:
1. Determine average rank per pathway within each method. After ranking P 
values (ties receive the average rank), average the ranks across the five methods to 
yield 1 rank per pathway.
2. Determine the expected distribution of averaged ranks under the null. (a) 
Calculate the Pearson correlation statistics between pairs of methods. Null data 
(generated from unrelated European CEU+TSI Hapmap3 GWAS data set via 
random phenotype assignment (100 cases, 100 controls)) from each method was 
used for these calculations. (b) Generate 5 sets of null P values (1 for each pathway 
drawn without replacement from the uniform distribution [0,1]) such that the 
intercorrelation among methods is preserved, using the method described at http://
comisef.wikidot.com/tutorial:correlateduniformvariates. Do this 10,000 times. (c) 
Transform P values into ranks for each permuted P value distribution. Note that in 
the permuted data, there will be few ties, if at all. Therefore, introduce ties by 
replacing the ranks for those pathways that tied in the real data with their average 
rank in the permuted data. (d) For each set of 5 permuted and ranked distributions, 
determine the average rank per pathway (as in Step 1).
3.
Assign empirical P values to each pathway. , where i = 0 if the 
permuted rank is greater than the real rank, and i = 1 if the permuted rank is less 
than or equal to the real rank. Note that this procedure does not allow for 
dependence between pathways, so it cannot be used to test whether there is an 
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excess of pathways with average rank achieving a given level of significance. 
However, it does give a valid test of significance for each pathway separately. To 
correct for multiple testing of pathways, q-values were calculated48. For each 
pathway, the q-value corresponds to the minimum value of the FDR at which that 
pathway would be declared significant.
Comparisons between methods: method overlap
To robustly test the significance of overlap in enriched pathways between methods, it is 
necessary to restrict the analysis to a set of independent pathways (by gene membership). 
This was done by pruning by Jaccard distance (see below). Note that such a restriction is not 
necessary and was not used for the pathway analysis combining methods, which uses the full 
set of pathways. To facilitate comparisons between methods, we use quantiles, not P values. 
Specifically, we focus on pathways that are in the top 25% for a particular method within a 
disease or null data set. This is because it is otherwise difficult to compare pathway P values 
from methods that have different statistical power. We use the following procedure to 
determine the extent to which methods overlap:
1. For a given data set, reduce the data set down to only pathways that are in the top 
25% in ≥1 of the methods;
2. Reduce redundancies in this data set by removing smaller pathways for which there 
exists a larger pathway whose Jaccard distance (intersection divided by the union) 
is ≥0.2;
3. Using this reduced data set, which represents a set of independent pathways that are 
in the top 25% of ≥1 of the methods, calculate all overlaps among five methods (5-
way, 4-way, 3-way and 2-way);
4. Calculate the expected overlap between pathways in the top 25% assuming top 
25% of pathways for each method is random.
Testing pathway overlap between diseases
In order to enable testing to be carried out for correlation in pathway enrichment P values 
and overlap in top pathways among diseases, a subset of 1,918 pathways was selected such 
that no two pathways had a Jaccard similarity measure >0.2. Initially, Pearson correlation 
coefficients were calculated between the pathway-specific enrichment P values of the null 
data set and each of the five disease data sets in turn. These correlations lay between 0.111 
and 0.156, with a mean of 0.132. This indicates that ranking pathways within methods and 
calculating the average rank across methods induces some correlation between pathway 
ranks between data sets. For example: ALIGATOR and INRICH only return a P value if a 
pathway contains at least two significant genes, otherwise the pathway was assigned equal 
bottom rank. Thus, small pathways are likely to have low ranks for these methods in most 
data sets. However, correlations between the diseases with respect to the pathway-specific 
enrichment P values were higher than those with the null or HIV (see Supplementary Tables 
5 and 14), suggesting that the interdisease correlation is not simply a function of 
methodological correlation.
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To test for significant correlation and overlap between the five disease data sets while 
allowing for correlations induced by the ranking method (as described above), we generated, 
for each pair of diseases, 1,000 random sets of 1,918 bivariate uniform variables with 
correlation of 0.132. The Pearson correlation of the two variables within each replicate data 
set was calculated and compared to that observed in the actual data. A similar method was 
used to compare the overlap in the top 10% of pathways between the two variables to that 
observed in the actual data. P values for these comparisons are shown in Supplementary 
Table 6. Correlation coefficients in the actual data were nominally significant for all pairs of 
the five diseases of interest (ADHD, ASD, BIP, MDD, SCZ), but not between these diseases 
and HIV or the null data set (with the exception of the HIV-MDD correlation, which was 
nominally significant but is likely to be an artifact of multiple testing).
Combining pathway enrichments across diseases
For each pathway, P values were combined across diseases using Brown’s method (an 
extension of Fisher’s method that accounts for correlation between data sets). This method is 
described49, but a brief description is provided here. To attain a joint test statistic for N tests 
that are not independent, the statistic has a mean m = 2N and a variance (σ2) where
and where pi and pj (i, j = 1,…, N) are the P values for each test and covariance (cov) is 
calculated as
for non-negative correlation coefficients ρij between the two P value distributions (here, set 
to be 0.132, which is the average correlation in P values between the disease data sets and 
the null, calculated in the previous section). Finally the overall significance of a set of non-
independent tests is calculated using the statistic T which under the null hypothesis follows 
the central chi-square distribution T = T0/c, with 2N/c degrees of freedom, where
and T0 is the sum of −2ln(p), as used in Fisher’s method.
This analysis was primarily performed on the three adult diseases (SCZ, BIP, MDD), which 
have larger and more powerful samples than the other diseases (ADHD, ASD). A secondary 
analysis of all five diseases was also performed. Finally, an analysis was performed 
combining SCZ, HIV and the null data set to confirm that pathway enrichments observed in 
the analysis of SCZ+BIP+MDD were due to shared biology rather than artifacts of the 
analysis method.
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When the diseases were tested separately, one pathway was significant after correction for 
multiple testing in BIP (GO:51568: histone H3-K4 methylation, q = 0.005) and MDD (GO:
8601: protein phosphatase Type 2A regulator activity, q = 0.012). No pathway achieved q < 
0.05 in the other diseases (or the null data set). When the three adult diseases were 
combined, 15 pathways were significant at q < 0.05, with the top pathway (GO:51568: 
histone H3-K4 methylation) having a q-value of 0.0005. These results are more significant 
than those observed in any of the diseases analyzed separately, and illustrate the power to be 
gained by combining pathway analyses across diseases with shared biology. When all five 
diseases were combined, GO:51568 was still significant (q = 0.045), although its 
significance was reduced due to lack of enrichment in ADHD or ASD. Finally, when SCZ 
was combined with HIV (not expected to share common biology with SCZ) and the null 
data set, no pathway was significant after multiple testing correction, as expected.
Supervised weighted coexpression network analysis
We performed a secondary analysis of 797 genes comprising all pathways with q < 0.1 from 
the primary cross disorder pathway enrichment analysis to explore how pathways relate to 
processes of in vivo brain development and aging. We asked how the genes cluster across 
brain regions and developmental time points using the BrainSpan exon array data18. We 
applied weighted gene coexpression network analysis50 to group genes into modules of 
coexpression. Modules were characterized for regional and temporal patterns as well as cell 
type specificity21.
Network analysis was performed using the WGCNA package in R. Gene-expression data 
were obtained from GSE25219 for 16,874 genes across 1,340 samples (75 individuals 
spanning 15 developmental stages with up to 16 brain regions per individual). Only regions 
with at least 10 samples were used, leaving 1,281 samples. After intersecting genes in the 
immune, synapse and methylation pathways, 797 genes were left for the network analysis, 
whose module parameters and membership are outlined in Supplementary Table 17. The 
specific parameters are made available in the supplemental R script for Figure 4 
(Supplementary Software). Similar modules were found with variations on these parameters.
The top 10 genes in each module are plotted in Figure 4a using the igraph package in R. 
Only correlations with r > 0.2 are shown, and the Fruchterman-Reingold force-directed 
algorithm as implemented in igraph was used to layout nodes using default parameters. 
Module expression profiles were summarized by taking the mean expression level of all 
genes in each module for each different brain region (across all time points) and each 
neurodevelopmental epoch (across all regions). We focused on relatively large changes 
between regions or time points (>75%), though statistical analysis of spatial and temporal 
patterns with Kruskal-Wallis tests and pairwise Mann-Whitney U-tests demonstrates many 
smaller differences are significant (due to the large sample size). In general, alternative 
methods for evaluating regional and temporal differences (for example, correlations with 
regional indicator variables, ANOVA with regions as factors) yielded similar patterns as 
those seen in Figure 4b. For simplicity of interpretation and discussion, we therefore chose 
to focus on these larger fold changes in order to highlight the most salient 
neurodevelopmental changes at the pathway level.
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Cell type–specific enrichment for modules was performed by using the cell specific 
expression analysis (CSEA) tool (http://genetics.wustl.edu/jdlab/csea-tool-2/). This tool 
contains cell type–specific genes that are derived from a translational profiling approach that 
isolates transcriptomes in mouse from specific, marker-defined cellular subpopulations21. 
We assessed each module for enrichment of lists for 35 broad and specific cell type gene 
sets (CSEA specificity threshold set to 0.05) across multiple brain regions in mouse, and 
corrected for multiple comparisons across 7 modules and the 35 cell type lists. We report 
enrichments at Benjamini-Hochberg corrected P < 0.05 in Figure 4c. The code underlying 
this analysis is included as Supplementary Software.
A Supplementary Methods Checklist is available.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Overview of statistical approach for integrative pathway analysis of GWAS data. A 
summary of an analysis of one disorder is shown. Simulated data were generated by drawing 
from a null pathway P-value distribution for each method and for each disease that 
accounted for correlations between methods. Pathway results from all disorders were 
subsequently combined using Fisher’s method.
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Figure 2. 
Quantile-quantile plot showing P-value distribution for a combined analysis combining 
results from five pathway analysis methods and six pathway databases. (a,b) Data are shown 
for schizophrenia (SCZ), bipolar disorder (BIP) and major depressive disorder (MDD; a) 
and SCZ, HIV acquisition and a null simulated data set (b).
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Figure 3. 
Multidimensional scaling plot of top 50 pathways with suggestive (<0.1) q-values ranked 
across five methods and three disorders (schizophrenia, bipolar disorder and major 
depressive disorder). The number of genes in each pathway is listed in Table 2. Color 
reflects rank (red represents top-ranking sets with lowest P values). Sizes reflect the number 
of genes in the set (maximum of 200, minimum of 11). See Supplementary Data for source 
data.
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Figure 4. 
Gene coexpression networks across brain development and regions for genes in all pathways 
with FDR < 0.1. (a) Network plot of ten hubs genes from each module showing clustering 
across neuroanatomical regions and developmental epochs. The nodes (genes) are annotated 
by gene-set membership while the edges reflect positive correlations across brain regions 
and development. (b) Regional and temporal patterns of gene expression as summarized by 
the average expression level of genes in each module. (c) Enrichment for cell type–specific 
genes across multiple brain regions and cell types; asterisks highlight enrichments passing 
FDR-adjusted P < 0.05.
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